Modular Medical CEO to Discuss Pivot Commercial Progress in Virtual Fireside Chat
Modular Medical said CEO Jeb Besser will discuss the commercial rollout of its Pivot tubeless patch pump during a virtual fireside chat on November 19, 2026.
Modular Medical, Inc. (NASDAQ:MODD) said Chief Executive Officer Jeb Besser is scheduled to take part in a virtual fireside chat on Thursday, November 19, 2026 at 10:30 a.m. ET. The discussion will focus on the company’s commercial progress and execution for its Pivot tubeless patch pump.
According to Modular Medical, Besser will address the ongoing phased rollout of Pivot across five U.S. regions. The rollout began in October 2026 and is continuing as the company prepares for an anticipated full-scale commercial launch in 2027.
Modular Medical is a commercial-stage medical device company developing insulin delivery technologies intended to simplify diabetes management and increase access to insulin pump therapy.
The Pivot tubeless patch pump is designed for people requiring intensive insulin therapy. The company describes the device as a user-friendly, flexible and accessible approach to insulin delivery.
Modular Medical said Pivot was developed to address barriers that have limited wider adoption of insulin pump therapy among patients managing diabetes with multiple daily injections.
Modular Medical said the timing and success of the phased rollout and planned full-scale commercial launch are subject to risks, trends and uncertainties. The company also identified uncertainties involving the development of its proprietary technologies, market acceptance of its products and services, anticipated consumer demand, its ability to manufacture products at high volumes, and economic, industry or political conditions in the United States or internationally.
The company said its forward-looking statements reflect its views as of the publication date and that it assumes no obligation to update them except as required by law.
Modular Medical announced that Chief Executive Officer Jeb Besser will participate in a virtual fireside chat about the company’s commercial progress and execution. The discussion will include the phased rollout of Pivot and progress towards the anticipated full-scale commercial launch in 2027.
Modular Medical’s virtual fireside chat is scheduled for Thursday, November 19, 2026 at 10:30 a.m. ET. The event will feature CEO Jeb Besser.
Modular Medical said Jeb Besser will provide an update on the company’s commercial progress and execution. The discussion will include the ongoing phased rollout of Pivot across five U.S. regions and progress towards the anticipated full-scale commercial launch in 2027.
Modular Medical said the phased rollout of Pivot across five U.S. regions began in October 2026. The company described the rollout as ongoing.
Modular Medical said it is progressing towards an anticipated full-scale commercial launch of Pivot in 2027. The company’s forward-looking statements identify the timing and success of the planned launch as subject to risks, trends and uncertainties.
Modular Medical said a replay of the fireside chat will be made available on its investor relations website following the event. A question-and-answer session will take place at the end of the discussion.
Investors can submit questions in advance to Modular Medical at [email protected]. The company said advance submissions are intended to help ensure questions are addressed during the Q&A session.
Modular Medical is a commercial-stage medical device company focused on developing insulin delivery technologies designed to simplify diabetes management and increase access to insulin pump therapy. Its Pivot tubeless patch pump is being prepared for full commercial launch.
Modular Medical’s Pivot tubeless patch pump is designed to provide a user-friendly, flexible and accessible approach to insulin delivery for people requiring intensive insulin therapy. The company said Pivot was developed to address barriers that have limited broader adoption of insulin pump therapy among patients managing diabetes with multiple daily injections.
Modular Medical said the timing and success of the phased rollout and planned full-scale commercial launch are subject to risks, trends and uncertainties. The company also identified risks including successful development of its proprietary technologies, market acceptance, anticipated consumer demand, high-volume manufacturing capability, and general economic, industry or political conditions in the United States or internationally.
Modular Medical shares trade on Nasdaq under the ticker symbol NASDAQ:MODD.